Generics Bulletin’s editorial team discusses recent conferences held by Medicines for Europe and the AAM, while looking ahead to the key off-patent industry events that are on the calendar over the next few months and beyond.
Generics Bulletin’s editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA’s Orange Book.
In a podcast discussion, Generics Bulletin’s editors talk about how you can enter and attend the Global Generics & Biosimilars Awards, what makes for a good entry, and why companies and individuals will want to get involved in the event.
With entries currently open for the Global Generics & Biosimilars Awards 2023 – which will take place on Wednesday 25 October at the Hotel Porta Fira in Barcelona – we talk through the categories that companies can enter, tips to make entries stand out, as well as the benefits of entering and attending the awards.
Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.
In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.
Hear all the details of the Global Generics & Biosimilars Awards 2020, now taking place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.
In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.
Pink Sheet's Brenda Sandburg talks to Prevision Policy’s Kate Rawson about who has the most at stake in the case, the questions she’ll be listening for during oral arguments, and what might be in store from the newest addition to the Supreme Court: Justice Neil Gorsuch.
US agency's Associate Director for Therapeutic Biologics Leah Christl gives the most up-to-date snapshot of biosimilar regulatory development, the potential areas for further FDA collaboration with European regulators – and how long it may be until the agency approves the first interchangeable biosimilar.
